Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis

Abstract

AbstractBackgroundSmall tyrosine kinase inhibitors (TKIs) show activity against breast cancer brain metastases (BCBM) of the human epidermal growth factor receptor 2 (HER2)‐positive subtype. This meta‐analysis aimed to objectively explore the efficacy and safety of TKIs.MethodsElectronic databases were searched for relevant clinical trials. We conducted a pairwise meta‐analysis, pooled analysis, and estimated summary survival curves to compare survival outcomes following TKIs therapy for BCBM patients using Stata version 16.0 or R x64 4.0.5.ResultsThirteen clinical trials involving 987 HER2‐positive BCBM patients were analyzed. A trend of longer progression‐free survival (PFS) was observed in the TKI‐containing arm compared to the non‐TKI‐containing arm (hazard ratio = 0.64, 95% confidence interval [CI]: 0.35–1.15, p = 0.132), although the difference is not statistically significant. Summary survival curves reported the summary median PFS and overall survival were 7.9 months and 12.3 months. Subgroup analysis revealed that TKIs combined with capecitabine (TKI + Cap) regimens resulted in improved survival outcomes. Tucatinib may be more effective in BCBM patients. The main grade 3–5 adverse events (AEs) were diarrhea (22%, 95% CI: 14%–32%), neutropenia (11%, 95% CI: 5%–18%), hepatic toxicity (7%, 95% CI: 1%–16%), and sensory neuropathy (6%, 95% CI: 2%–12%).ConclusionTKIs therapy improved the survival outcomes of HER2‐positive BCBM patients, especially when combined with capecitabine and tolerable AEs. We also identified the clinical value of tucatinib, which appears to be the most favorable TKI drug for BCBM patients.